布莱根妇女医院基底细胞癌T分期系统可识别转移与死亡风险患者
该研究基于488例原发性基底细胞癌(BCC)队列,开发布莱根妇女医院(BWH)T分期系统,并与AJCC第8版T分期比较预测转移/死亡的表现。BWH与AJCC8在高分期均捕获全部转移/死亡,但BWH T2纳入的≥2 cm病例比AJCC8 T3/T4少54%,特异度(0.92 vs 0.80,P < .001)与阳性预测值(24% vs 11%,P < .001)更高,C统计量更优(P < .001)。BWH T2的10年转移/死亡累积发生率为37%(95%CI 21%-60%)。
要点
- BWH与AJCC8高分期均捕获全部转移/死亡,但BWH所需病例数约减半。
- BWH T2识别转移/死亡风险的特异度和阳性预测值均显著优于AJCC8 T3/T4。
- BWH T2的10年转移/死亡累积发生率为37%,足以支持复发监测与辅助治疗临床试验。
核心结论
- BWH与AJCC8 T分期均能在高分期捕获全部转移和死亡,但BWH以约一半的病例数实现,减少不适当的上分期。
- BWH T2 BCC的转移或死亡风险足以支持复发监测和辅助治疗临床试验。
研究设计与样本
- BWH T分期系统基于既往发表的488例原发性BCC嵌套队列开发。
- 肿瘤分别按BWH与AJCC8 T分期系统进行分期,并比较对转移和/或死亡的预测表现。
- 研究为两中心队列。
主要发现
- BWH与AJCC8 T分期均在高T分期(BWH为T2;AJCC8为T3/T4)捕获全部转移/死亡。
- BWH T2纳入的≥2 cm病例比AJCC8 T3/T4少54%。
- BWH识别转移/死亡风险的特异度为0.92,AJCC8为0.80(P < .001)。
- BWH阳性预测值为24%,AJCC8为11%(P < .001);BWH的C统计量更优(P < .001)。
- BWH T2的10年转移/死亡累积发生率为37%(95%CI 21%-60%)。
关键数值与推荐
- BWH高分期为T2,AJCC8高分期为T3/T4,两者均捕获全部转移/死亡。
- BWH T2中≥2 cm病例数比AJCC8 T3/T4少54%。
- BWH特异度0.92 vs AJCC8 0.80(P < .001);阳性预测值24% vs 11%(P < .001)。
- BWH T2的10年转移/死亡累积发生率为37%(95%CI 21%-60%)。
临床怎么用
- 可采用BWH T分期识别BCC转移/死亡高风险患者,同时减少不适当上分期。
- 对BWH T2患者应考虑复发监测,并可纳入辅助治疗临床试验。
局限性
- 研究为两中心队列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite approximately 4400 locally advanced US cases annually, high-stage basal cell carcinoma (BCC) is ill-defined. OBJECTIVE: To develop a tumor (T) staging system for BCC that will predict metastasis/death and compare its performance with that of the American Joint Committee on Cancer 8th edition (AJCC8) T-staging system. METHODS: Brigham and Women's Hospital (BWH) T staging was developed from a previously published nested cohort of 488 primary BCCs. Tumors were staged via BWH and AJCC8 T-staging systems, and predictions of metastasis and/or death were compared. RESULTS: The BWH and AJCC8 T-staging systems both captured all metastases/deaths in high T stages (BWH, T2; AJCC8, T3/T4). BWH T2 included 54% fewer cases ≥2 cm than AJCC8 T3/T4. BWH had a higher specificity (0.92 vs 0.80; P < .001) and positive predictive value (24% vs 11%, P < .001) for identifying cases at risk for metastasis/death, and the C-statistic was superior for BWH (P < .001). The BWH T2 10-year cumulative incidence of metastasis/death was 37% (95% confidence interval, 21%-60%). LIMITATIONS: Two-center cohort. CONCLUSIONS: BWH and AJCC 8 BCC staging both capture all metastases and deaths in the upper stages. However, BWH staging does so in half the number of cases, thus minimizing inappropriate up-staging. The risk of metastasis or death in BWH T2 BCC is sufficient to warrant surveillance for recurrence and clinical trials of adjuvant therapy.
引用
- Morgan FC, Ruiz ES, Karia PS, et al. Brigham and Women's Hospital tumor classification system for basal cell carcinoma identifies patients with risk of metastasis and death. J Am Acad Dermatol. 2021. PMID: 33497751. doi:10.1016/j.jaad.2021.01.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。